Chemotherapeutic Advancements in Peripheral T-Cell Lymphoma

Seminars in Hematology

Volumn 51, Issue 1, 2014, Pages 17-24

  Reddy, Nishitha M ^a   Evens, Andrew M ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CISPLATIN; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PENTOSTATIN; PRALATREXATE; PREDNISONE; RANIMUSTINE; ROMIDEPSIN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; ZIDOVUDINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; SALVAGE THERAPY; SUBCUTANEOUS T CELL LYMPHOMA; T CELL LEUKEMIA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; PROGNOSIS; RECURRENCE;

EID: 84892854428     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.11.006     Document Type: Article

References (56)

1. Savage K.J. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2008, 280-288.
2. Foss F.M., Zinzani P.L., Vose J.M., et al. Peripheral T-cell lymphoma. Blood 2011, 117:6756-6767.
3. Vose J., Armitage J., Weisenburger D., et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
4. Zelenetz A.D., Wierda W.G., Abramson J.S., et al. Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw 2013, 11:257-272.
5. Savage K.J., Chhanabhai M., Gascoyne R.D., et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004, 15:1467-1475.
6. Evens A.M., Feldman T., Kroll A., et al. Survival of newly diagnosed T-cell lymphoma (TCL) in the modern era: investigation of prognostic factors with critical examination of therapy in a multicenter US cohort. Blood (ASH Annual Meeting Abstracts) 2012, 120:2728a.
7. Belhadj K., Reyes F., Farcet J.P., et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003, 102:4261-4269.
8. Dearden C. How I treat prolymphocytic leukemia. Blood 2012, 120:538-551.
9. Gisselbrecht C., Lepage E., Molina T., et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002, 20:2472-2479.
10. Simon A., Peoch M., Casassus P., et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 2010, 151:159-166.
11. Tilly H., Lepage E., Coiffier B., et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003, 102:4284-4289.
12. Yamazaki T., Sawada U., Kura Y., et al. Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study. Acta Haematol 2006, 116:90-95.
13. d'Amore F., Relander T., Lauritzsen G., et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-Cell lymphomas (PTCL)-a phase II study of the Nordic Lymphoma Group (NLG). Blood (ASH Annual Meeting Abstracts) 2006, 108:401.
14. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634-641.
15. Niitsu N., Hayama M., Yoshino T., et al. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers. Br J Haematol 2011, 153:582-588.
16. Peng Y.L., Huang H.Q., Lin X.B., et al. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen]. Ai Zheng 2004, 23:943-946.
17. Escalon M.P., Liu N.S., Yang Y., et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005, 103:2091-2098.
18. Mak V., Hamm J., Chhanabhai M., et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013, 31:1970-1976.
19. Savage K.J., Harris N.L., Vose J.M., et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008, 111:5496-5504.
20. de Jong D., Vasmel W.L., de Boer J.P., et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA 2008, 300:2030-2035.
21. Kim B., Roth C., Chung K.C., et al. Anaplastic large cell lymphoma and breast implants: a systematic review. Plast Reconstr Surg 2011, 127:2141-2150.
22. Tsukasaki K., Utsunomiya A., Fukuda H., et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group study JCOG9801. J Clin Oncol 2007, 25:5458-5464.
23. Matutes E., Taylor G.P., Cavenagh J., et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 2001, 113:779-784.
24. Hermine O., Allard I., Levy V., et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002, 3:276-282.
25. Kchour G., Tarhini M., Kooshyar M.M., et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113:6528-6532.
26. Salhany K.E., Macon W.R., Choi J.K., et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 1998, 22:881-893.
27. Hoque S.R., Child F.J., Whittaker S.J., et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol 2003, 148:516-525.
28. Willemze R., Jansen P.M., Cerroni L., et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group study of 83 cases. Blood 2008, 111:838-845.
29. Willemze R., Jaffe E.S., Burg G., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785.
30. Marzano A.V., Berti E., Paulli M., et al. Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol 2000, 136:889-896.
31. Briki H., Bouaziz J.D., Molinier-Frenkel V., et al. Subcutaneous panniculitis-like T-cell lymphoma alphabeta: complete sustained remission with corticosteroids and methotrexate. Br J Dermatol 2010, 163:1136-1138.
32. Gale J., Simmonds P.D., Mead G.M., et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000, 18:795-803.
33. Jantunen E., Boumendil A., Finel H., et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood 2013, 121:2529-2532.
34. Falchook G.S., Vega F., Dang N.H., et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 2009, 20:1080-1085.
35. Corazzelli G., Capobianco G., Russo F., et al. Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas. Haematologica 2005, 90. ECR14.
36. Iannitto E., Barbera V., Quintini G., et al. Hepatosplenic gammadelta T-cell lymphoma: complete response induced by treatment with pentostatin. Br J Haematol 2002, 117:995-996.
37. Grigg A.P. 2'-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma. Leuk Lymphoma 2001, 42:797-799.
38. Jaeger G., Bauer F., Brezinschek R., et al. Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 2008, 19:1025-1026.
39. Mittal S., Milner B.J., Johnston P.W., et al. A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol 2006, 76:531-534.
40. Chanan-Khan A., Islam T., Alam A., et al. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2004, 45:1673-1675.
41. Voss M.H., Lunning M.A., Maragulia J.C., et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 2013, 13:8-14.
42. Zinzani P.L., Magagnoli M., Bendandi M., et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 1998, 9:1351-1353.
43. Sallah S., Wan J.Y., Nguyen N.P. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001, 113:185-187.
44. Yao Y.Y., Tang Y., Zhu Q., et al. Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. Leuk Lymphoma 2013, 54:1194-1200.
45. Mahadevan D., Unger J.M., Spier C.M., et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 2013, 119:371-379.
46. Coiffier B., Pro B., Prince H.M., et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012, 30:631-636.
47. Dang N.H., Pro B., Hagemeister F.B., et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 136:439-447.
48. Foss F.M., Sjak-Shie N., Goy A., et al. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma 2013, 54:1373-1379.
49. Zinzani P.L., Musuraca G., Tani M., et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:4293-4297.
50. Evens A.M., Rosen S.T., Helenowski I., et al. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. Br J Haematol 2013, 163:55-61.
51. Kim S.J., Yoon D.H., Kang H.J., et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 2012, 48:3223-3231.
52. Dashnamoorthy R., Kdela I., Bhalla S., et al. The novel 2nd generation proteasome inhibitor MLN9708 induces redox and MAPK-dependent cell death in T-cell lymphoma (TCL) and Hodgkin lymphoma (HL) cell lines and human lymphoma xenograft models 2013, 12th International Conference on Malignant Lymphoma (12-ICML), Lugano, Switzerland, [abstract 117].
53. Kim J.G., Sohn S.K., Chae Y.S., et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007, 60:129-134.
54. Gallamini A., Zaja F., Patti C., et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007, 110:2316-2323.
55. Advani R.H., Hong F., Horning S.J., et al. Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Leuk Lymphoma 2012, 53:718-720.
56. Damaj G., Gressin R., Bouabdallah K., et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013, 31:104-110.